Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaji Hashimoto

Showing results (151-160 of 168) with videos related to

Pageof 17
Sort By:
Oncology|March 1, 2022
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular CarcinomaYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Annals of Gastroenterological Surgery|July 27, 2019
Surgical outcomes of gastroenterological surgery in Japan: Report of the National Clinical Database 2011-2017Hiroshi Hasegawa, Arata Takahashi, Yoshihiro Kakeji, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 26, 2024
Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapyYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary reportYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Oncology|June 17, 2021
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib TreatmentYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Internal Medicine (Tokyo, Japan)|September 23, 2020
Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with LenvatinibKayoko Kasuya, Yusuke Kawamura, Masahiro Kobayashi, et al.
Surgery Today|July 19, 2020
Development of gastroenterological surgery over the last decade in Japan: analysis of the National Clinical DatabaseYoshihiro Kakeji, Hiroyuki Yamamoto, Hideki Ueno, et al.
Internal Medicine (Tokyo, Japan)|September 13, 2021
Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib TreatmentNozomu Muraishi, Yusuke Kawamura, Masahiro Kobayashi, et al.
Oncology|November 18, 2020
Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib TreatmentDaiki Yamashige, Yusuke Kawamura, Masahiro Kobayashi, et al.
Cancer Research|September 3, 2009
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinomaYujin Hoshida, Sebastian M B Nijman, Masahiro Kobayashi, et al.
Pageof 17

Showing results (151-160 of 168) with videos related to

Sort By:
Pageof 17
Oncology|March 1, 2022
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular CarcinomaYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Annals of Gastroenterological Surgery|July 27, 2019
Surgical outcomes of gastroenterological surgery in Japan: Report of the National Clinical Database 2011-2017Hiroshi Hasegawa, Arata Takahashi, Yoshihiro Kakeji, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 26, 2024
Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapyYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary reportYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Oncology|June 17, 2021
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib TreatmentYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Internal Medicine (Tokyo, Japan)|September 23, 2020
Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with LenvatinibKayoko Kasuya, Yusuke Kawamura, Masahiro Kobayashi, et al.
Surgery Today|July 19, 2020
Development of gastroenterological surgery over the last decade in Japan: analysis of the National Clinical DatabaseYoshihiro Kakeji, Hiroyuki Yamamoto, Hideki Ueno, et al.
Internal Medicine (Tokyo, Japan)|September 13, 2021
Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib TreatmentNozomu Muraishi, Yusuke Kawamura, Masahiro Kobayashi, et al.
Oncology|November 18, 2020
Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib TreatmentDaiki Yamashige, Yusuke Kawamura, Masahiro Kobayashi, et al.
Cancer Research|September 3, 2009
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinomaYujin Hoshida, Sebastian M B Nijman, Masahiro Kobayashi, et al.
Pageof 17